The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), considered the safest in this particular patients setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and safety in patients with cancer, their use can be challenging in patients with hematologic malignancies due to the peculiarity of these neoplasms: high thrombotic risk, possible onset of thrombocytopenia and concomitant anticancer therapies. The aim of our study was to evaluate the efficacy and safety of DOACs for venous thromboembolism or atrial fibrillation in patients with hematologic malignancies and plasmatic DOACs level during anticancer therapy and at time of bleeding or thrombotic complications. We evaluated patients with hematologic malignancies treated with DOACs for venous thromboembolism or atrial fibrillation; therapy was maintained until the platelet count was ≥50x109 /L. In case of concomitant anticancer treatment and hemorrhagic or thrombotic events, we checked DOACs plasma levels (trough and peak). The patients evaluated were 135:104/135 were on anticancer therapy. We did not observe either thrombotic or major hemorrhagic adverse events. Minor bleedings occurred in 10 patients and clinical relevant non major (CRNM) in 2 patients. There was a statistically significant correlation between bleedings and myelodysplastic syndrome. DOACs resulted effective and safe in patients with hematologic malignancies. DOACs plasma level can be helpful in suggesting an early dose adjustment to prevent hemorrhagic adverse event in patients on concomitant anticancer therapy. Larger prospective studies including hematologic patients are warranted to confirm the safety and efficacy of DOACs. This article is protected by copyright. All rights reserved.

Direct Oral Anticoagulants In Patients With Hematologic Malignancies / Serrao, Alessandra; Fiori, Luciano; Santoro, Cristina; De Luca, Maria Lucia; Ferretti, Antonietta; De Luca, Giulia; Ligia, Silvio; Lapietra, Gianfranco; Mohamed, Sara; Breccia, Massimo; Chistolini, Antonio. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2020). [10.1002/hon.2770]

Direct Oral Anticoagulants In Patients With Hematologic Malignancies

Serrao, Alessandra;Fiori, Luciano;Santoro, Cristina;De Luca, Maria Lucia;Ferretti, Antonietta;De Luca, Giulia;Ligia, Silvio;Lapietra, Gianfranco;Mohamed, Sara;Breccia, Massimo;Chistolini, Antonio
2020

Abstract

The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), considered the safest in this particular patients setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and safety in patients with cancer, their use can be challenging in patients with hematologic malignancies due to the peculiarity of these neoplasms: high thrombotic risk, possible onset of thrombocytopenia and concomitant anticancer therapies. The aim of our study was to evaluate the efficacy and safety of DOACs for venous thromboembolism or atrial fibrillation in patients with hematologic malignancies and plasmatic DOACs level during anticancer therapy and at time of bleeding or thrombotic complications. We evaluated patients with hematologic malignancies treated with DOACs for venous thromboembolism or atrial fibrillation; therapy was maintained until the platelet count was ≥50x109 /L. In case of concomitant anticancer treatment and hemorrhagic or thrombotic events, we checked DOACs plasma levels (trough and peak). The patients evaluated were 135:104/135 were on anticancer therapy. We did not observe either thrombotic or major hemorrhagic adverse events. Minor bleedings occurred in 10 patients and clinical relevant non major (CRNM) in 2 patients. There was a statistically significant correlation between bleedings and myelodysplastic syndrome. DOACs resulted effective and safe in patients with hematologic malignancies. DOACs plasma level can be helpful in suggesting an early dose adjustment to prevent hemorrhagic adverse event in patients on concomitant anticancer therapy. Larger prospective studies including hematologic patients are warranted to confirm the safety and efficacy of DOACs. This article is protected by copyright. All rights reserved.
2020
atrial fibrillation; direct oral anticoagulants; hematologic malignancies; venous thromboembolism
01 Pubblicazione su rivista::01a Articolo in rivista
Direct Oral Anticoagulants In Patients With Hematologic Malignancies / Serrao, Alessandra; Fiori, Luciano; Santoro, Cristina; De Luca, Maria Lucia; Ferretti, Antonietta; De Luca, Giulia; Ligia, Silvio; Lapietra, Gianfranco; Mohamed, Sara; Breccia, Massimo; Chistolini, Antonio. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2020). [10.1002/hon.2770]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1433407
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 5
social impact